Drug Trial Radar · NCT06669000
Time Required to Dissolve Urate Deposits
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Sep 24, 2024
Primary completion
Sep 24, 2032
Study completion Sep 24, 2032
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut National de la Santé Et de la Recherche Médicale, France; ART VIGGO Association for Research
- First posted
- Nov 1, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy). The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees. The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.
Conditions
- Gout
Interventions
Standard X-RaysDiagnostic test
\- Standard X-Rays: feet (Month 0)
UltrasoundDiagnostic test
\- Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
DECT of feetDiagnostic test
DECT of feet: in tophaceous patients only (Month 0, Month 24)
DNA sampleBiological
DNA will be collected at Month 0
Serum collectionBiological
\- Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time required for complete dissolution of urate depositsTime frame: Change between baseline (month 0) and up to 48 months after initiation of ULT
Locations
1 site in 1 country. Site status is shown where the registry gives one.
APHP, Lariboisière Hospital, Rheumatology departement
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.